About OJO | Search | Ahead of print | Current Issue | Archives | Author Instructions | Reviewer Guidelines | Online submissionLogin 
Oman Journal of Ophthalmology Oman Journal of Ophthalmology
  Editorial Board | Subscribe | Advertise | Contact
https://www.omanophthalmicsociety.org/ Users Online: 626  Wide layoutNarrow layoutFull screen layout Home Print this page  Email this page Small font size Default font size Increase font size


 
 Table of Contents    
ORIGINAL ARTICLE
Year : 2011  |  Volume : 4  |  Issue : 2  |  Page : 63-66  

Half-fluence photodynamic therapy to treat chronic central serous chorioretinopathy: A case series


Department of Ophthalmology, Sultan Qaboos University Hospital, Oman

Date of Web Publication10-Aug-2011

Correspondence Address:
Ahmed S Al-Hinai
Postal code 132, PO box 857, Al-Khod, Seeb, Muscat
Oman
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0974-620X.83655

Rights and Permissions
   Abstract 

Objective : To evaluate the efficacy and safety of half-fluence photodynamic therapy (PDT) in treating chronic central serous chorioretinopathy (CSC) in Omani population.
Materials and Methods : A Retrospective chart review of all patients with chronic CSC treated with half-fluence PDT from November 2009 to December 2010 was carried out. Recorded parameters included best-corrected visual acuity, findings of clinical examination, results of fluorescein angiography and optical coherence tomography at baseline and during follow-up visits after treatment.
Results : Six eyes (of five Omani patients) with chronic CSC, of at least 9 months duration, were treated with half-fluence PDT. All eyes showed a complete resolution of CSC within 1 month following treatment. Four eyes showed visual improvement and two had unchanged stable vision. No complications from the treatment were noticed during the follow-up visits.
Conclusion : Half-fluence PDT to treat chronic CSC in Omani population is a promising treatment that results in both structural and functional improvement.

Keywords: Central serous chorioretinopathy, half-fluence photodynamic therapy, Omani, verteporfin


How to cite this article:
Al-Hinai AS, Al-Abri MS. Half-fluence photodynamic therapy to treat chronic central serous chorioretinopathy: A case series. Oman J Ophthalmol 2011;4:63-6

How to cite this URL:
Al-Hinai AS, Al-Abri MS. Half-fluence photodynamic therapy to treat chronic central serous chorioretinopathy: A case series. Oman J Ophthalmol [serial online] 2011 [cited 2019 Aug 20];4:63-6. Available from: http://www.ojoonline.org/text.asp?2011/4/2/63/83655


   Introduction Top


Central serous chorioretinopathy (CSC), which is also known as Central Serous Retinopathy (CSR), is an acquired macular disease typically affecting young males. Males account for 72-88% of the affected population. [1] It is bilateral in up to 40% of cases. [1] The most common symptoms are reduced vision and micropsia. Fundus examination shows one of three presentations: neurosensory detachment, pigment epithelium detachment (PED), or mixed type. The pathogenesis of CSC is still not completely understood. One theory suggests that fluid from choroid escapes into subretinal space through a defect in tight junctions between the retinal pigment epithelium (RPE) cells. [2] Another suggests that RPE cells lose their normal polarity and pump fluid from the choroid toward the retina, causing a neurosensory detachment. [2]

Studying the abnormalities of choroidal circulation in CSC by indocyanine green (ICG) has led to new theories regarding pathogenesis of CSC. In many patients, ICG reveals multifocal areas of choroidal vascular hyperpermeability which may lead to mechanical disruption of the RPE barrier with subsequent subretinal fluid accumulation. [2] Metabolic stress on the RPE was observed in cases of CSC. [3] Risk factors for CSC are: personality type-A, steroid use, pregnancy, alcohol use, antibiotic use, antihistamine use, autoimmune diseases, tobacco use, and untreated hypertension. [4]

Observation is usually the initial step in treating patients with acute CSC. The followings are indications to treat CSC: persistent or chronic CSC (>3-4 months), recurrences in eyes with visual deficits from CSC, visual deficits in the fellow eye from CSC, presence of chronic changes like cysts, and occupational reasons. [5] Treatment options include laser photocoagulation (argon or micropulse diode lasers) and/or photodynamic therapy (PDT). [6],[7],[8],9[],[10],[11],[12],[13],[14],[15]

PDT has some advantages over laser photocoagulation in treating CSC. Permanent scotomas and scar formation with permanent foveal damage are known adverse effects from macular photocoagulation. [7],[16] On the other hand, PDT does not have clinically visible structural damage and it usually will not result in persistent scotomas. However, some studies showed that standard dose PDT might be associated with choriocapillaris hypoperfusion that may result in decreased vision. [15],[17] The standard regime for using PDT is to give a patient intravenous verteporfin at a dose of 6 mg/m 2 over 10 minutes. Then, 5 minutes later, diode laser at a wavelength of 689 nm and energy of 50 mJ/cm 20 over 83 seconds is directed to the target lesion of the eye. The laser spot size is adjustable according to the lesion size. In this case series, we report the efficacy and safety of half-fluence PDT in the treatment of five Omani patients (six eyes) with chronic CSC. The dose of verteporfin used is similar to what is recommended by FDA, but laser energy of 25 mJ/cm 2 (half fluence) over 83 seconds was applied to the lesion.


   Materials and Methods Top


All patients with chronic CSC who presented to the Department of Ophthalmology at the Sultan Qaboos University Hospital (SQUH) between November 2009 and December 2010 were included in the study. All patients had been evaluated by one retina specialist (AA). Diagnosis of CSC was based on clinical findings and ancillary tests such as fundus fluorescein angiography (FFA) and optical coherence tomography (OCT). Distance visual acuity was assessed with the Early Treatment Diabetic Retinopathy (ETDRS) chart. Macular OCT and FFA were performed in all patients prior to the treatment. Treatment with PDT was initiated once a complete ophthalmic assessment was done. ICG study was not performed because of unavailability. The spot size of treatment was measured by using the fluorescein images. The delivered laser energy, which was used during treatment sessions, was half of the standard dose (half-fluence PDT), i.e. 25 mj/cm 2 over 83 seconds. Intravenous verteporfin was given at a dose of 6 mg/m 2 over 10 minutes as recommended by FDA. All patients were admitted to the hospital for the treatment and instructed to avoid sun exposure for 3 days post-treatment. Chart review of electronic medical records for these patients was done to collect appropriate data. Follow-up visits were at months 1, 3, 6 and 12 post-treatment. OCT was done for all patients in all follow-up visits. FFA was not done post-treatment for all patients, since they all showed improvement clinically and by OCT in all visits.


   Results Top


The demographic details, duration of CSC and follow-up periods for the study patients are given in [Table 1]. All patients were of Omani origin. There were three males and two females. The average age was 41 years (range 34-50 years). Three patients (two males and one female) had bilateral chronic CSC and the two other patients had unilateral chronic CSC. All patients had been referred from other institutions for management. No prior therapy had been instituted.

All patients had CSC for at least 9 months. Five eyes (out of eight) had a neurosensory detachment type of CSC, two had PED, and one had a mixed type of CSC. The average duration of CSC in all patients was 3 years (range 9 month to 10 years). All patients had undergone FFA and OCT prior to the treatment [Figure 1].
Table 1: Demographic features of patients


Click here to view
Figure 1: Early and late phase of FFA for left eye of patient no. 1 shows leaking hyperfluorescence in ink-dot, expansile pattern

Click here to view


Two patients (no. 1 and 2) with bilateral CSC received PDT only in one eye because the visual acuity in the non-treated eye was 6/6. The average period of follow-up for all patients was 7 months (range 2-12 months). [Table 2] summarizes the five patients with pre- and post-PDT macular status and best-corrected visual acuity (BCVA) [Figure 2] and [Figure 3].
Table 2: Pre- and post-PDT macular status and BCVA in all patients


Click here to view
Figure 2: Fundus fluorescein angiography and optical coherence tomography of both eyes of patient no. 5 pre-photodynamic therapy. Upper images row (a, b, c) for right eye shows early and late phases of fundus fluorescein angiography and optical coherence tomography. Lower images row (d, e, f) for left eye shows early and late phases of fundus fluorescein angiography and optical coherence tomography

Click here to view
Figure 3: Optical coherence tomography of both eyes of patient no. 5 post-photodynamic therapy: (a) right eye; (b) left eye

Click here to view


Of eight eyes with chronic CSC, six were treated with the half-fluence PDT. All treated eyes showed a complete resolution of the CSC within 1 month of therapy. Persistent neurosensory CSC was seen in one of the untreated eyes, but with 6/6 visual acuity (left eye of patient no. 1). On the other hand, an untreated eye with PED-type CSC had a complete resolution of the PED after the fellow eye was treated (left eye of patient no. 2).

Of the six treated eyes, visual acuity improved in four eyes and remained unchanged in two eyes. There was no deterioration of visual acuity after PDT in any eye. The improvement of visual acuity (VA) in the four eyes was more than double (from pre-PDT VA average logMAR 0.40 to post-PDT VA average logMAR 0.15). For all six treated eyes, mean improvement in acuity was from logMAR value of 0.38 to 0.19. During the follow-up period, no recurrence of CSC was observed in any eye. In addition, there was no deterioration of visual acuity or other adverse effects.


   Discussion Top


CSC is a common acquired maculopathy. Acute CSC usually resolves spontaneously with very good visual acuity. [18] However, chronic CSC may need treatment since vision can be permanently affected. [19] Laser photocoagulation was used for decades before the era of PDT. However, laser photocoagulation may not accelerate resolution and does not reduce the recurrence rate. [6] In addition, it may result in permanent visual defects. [7]

In our case series in Omani patients, results showed that middle-aged males are more affected than females with CSC and bilateral disease is more common than unilateral. These conclusions are similar to what has been found in previous studies. [1],[4] All treated eyes responded well within 1 month after a single session of half-fluence PDT. A previous study in Omani patients with CSC showed complete resolution of unilateral CSC with a single session of PDT. [20] The dose of delivered energy was not mentioned in that study.

Of the six treated eyes, four showed improvement in visual acuity after therapy. The remaining two eyes with unchanged acuity were right eye of patient no. 4 and right eye of patient no. 5. The first had neurosensory detachment type of CSC for around 10 years. The prolonged period of such CSC might result in permanent damage to photoreceptors, and hence, permanent visual loss. The second eye had a mixed-type of CSC for around 2 years. The longstanding CSC could also be the reason of non-improvement in vision of that eye. We can conclude that long duration of CSC is a risk factor for permanent visual loss.

Verteporfin was approved by FDA in 2000 to treat wet age-related macular degeneration by light sensitization (PDT). It started to be used in the treatment of CSC soon after that. [11] The mechanism of action in treating CSC is not fully clear. However, it is believed that short-term hypoperfusion of choriocapillaris occurs followed by remodeling of choroidal vessels. [3],[8],[9],[10],[18]

Multiple studies showed that PDT is a useful treatment for acute and chronic CSC. [8],[9],[11],[15] Most of these studies were performed with the use of standard-fluence PDT, in which 50 mJ/cm 2 of energy was used. However, half-fluence PDT (25 mJ/cm 2 ) was only investigated in two studies, in which a comparison between standard fluence and half fluence was made. [14],[21] These studies concluded that there was no difference of visual acuity and subretinal fluid reabsorption between both regimes. However, atrophic changes and choroidal neovascularization developed in two patients treated with standard-fluence PDT. [14] In addition, there was a significant reduction of choriocapillaris perfusion in the standard-fluence PDT group. [21] In our study, all treated eyes received half-fluence PDT and no adverse effects were observed. However, one eye (left eye of patient no. 2) with PED-type CSC of 1-year duration showed a complete resolution although treatment targeted the fellow eye. Spontaneous resolution of CSC of that eye is not understood.

Patients with CSC usually have good visual prognosis with a favorable natural course. However, few need treatment. PDT is currently used to treat CSC with promising results for both acute and chronic types. A non-comparative study carried out for acute CSC, in which half-dose verteporfin with standard-fluence PDT was used, showed a successful outcome. [13] Recent studies have also investigated the role of anti-vascular endothelial growth factors (bevacizumab) as a treatment for this disorder, with promising results in terms of visual acuity and anatomical restoration, although the sample size was small (six patients). [22] Another study showed shortening of resolution time of CSC by using acetazolamide. [23] Half-fluence PDT, rather than full dose of delivered energy, should be studied in a larger sample size to draw strong conclusions about this modality of treatment for chronic CSC.

 
   References Top

1.Wang M, Munch IC, Hasler PW, Prünte C, Larsen M. Central serous chorioretinopathy. Acta Ophthalmol 2008;86:126-45.  Back to cited text no. 1
    
2.Ryan SJ. Retina textbook. Vol. 2. 4th edition. Mosby. USA. 2006. p. 1135-6.  Back to cited text no. 2
    
3.Field MG, Elner VM, Park S, Hackel R, Heckenlively JR, Elner SG, et al. Detection of retinal metabolism stress resulting from central serous retinopathy. Retina 2009;29:1162-6.  Back to cited text no. 3
[PUBMED]  [FULLTEXT]  
4.Haimovici R, Koh S, Gagnon DR, Lehrfeld T, Wellik S. Risk factors for central serous chorioretinopathy. Ophthalmology 2004;111:244-9.   Back to cited text no. 4
    
5.Basic and Clinical Science Course. American Academy of Ophthalmology; Section 12, Retina and vitreous, Issue 2004-2005. p. 54.  Back to cited text no. 5
    
6.Ficker L, Vafidis G, White A, Leaver P. Long-term follow-up of prospective trial of argon laser photocoagulation in the treatment of central serous retinopathy. Br J Ophthalmol 1988;72:829-34.  Back to cited text no. 6
    
7.Verma L, Sinha R, Venkatesh P, Tewari HK. Comparative evaluation of diode laser versus argon laser photocoagulation in patients with central serous retinopathy: A pilot, randomized controlled trial. BMC Ophthalmol 2004;4:15.  Back to cited text no. 7
[PUBMED]  [FULLTEXT]  
8.Chan WM, Lam DS, Lai TY, Tam BS, Liu DT, Chan CK. Choroidal vascular remodeling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: A novel treatment. Br J Ophthalmol 2003;87:1453-8.  Back to cited text no. 8
    
9.Taban M, Boyer DS, Thomas EL, Taban M. Chronic central serous chorioretinopathy: Photodynamic therapy. Am J Ophthalmol 2004;137:1073-80.   Back to cited text no. 9
[PUBMED]  [FULLTEXT]  
10.Schmidt-Erfurth U, Hasan T. Mechanism of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration. Surv Ophthalmol 2000;45:195-214.  Back to cited text no. 10
[PUBMED]  [FULLTEXT]  
11.Canakis C, Livir-Rallatos C, Panayiotis Z, Livir-Rallatos G, Persidis E, Conway MD, et al. Ocular photodynamic therapy for serous macular detachment in the diffuse retinal pigment epitheliopathy variant of idiopathic central serous chorioretinopathy. Am J Ophthalmol 2003;136:750-2.  Back to cited text no. 11
[PUBMED]  [FULLTEXT]  
12.Chan WM, Lam DS, Lai TY, Yuen KS, Liu DT, Chan CK, et al. Treatment of choroidal neovascularization in central serous chorioretinopathy by photodynamic therapy with verteporfin. Am J Ophthalmol 2003;136:836-45.  Back to cited text no. 12
[PUBMED]  [FULLTEXT]  
13.Chan WM, Lai TY, Lai RY, Liu DT, Lam DS. Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy. Ophthalmology 2008;115:1756-65.  Back to cited text no. 13
[PUBMED]  [FULLTEXT]  
14.Ober MD, Yannuzzi LA, Do DV, Spaide RF, Bressler NM, Jampol LM, et al. Photodynamic therapy for focal retinal pigment epithelial leaks secondary to central serous chorioretinopathy. Ophthalmology 2005;112:2088-94.  Back to cited text no. 14
[PUBMED]  [FULLTEXT]  
15.Chan WM, Lai TY, Lai RY, Tang EW, Liu DT, Lam DS. Safety enhanced photodynamic therapy for chronic central serous chorioretinopathy: One-year results of a prospective study. Retina 2008;28:85-93.  Back to cited text no. 15
[PUBMED]    
16.Laser photocoagulation of subfoveal recurrent neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Macular Photocoagulation Study Group. Arch Ophthalmol 1991;109:1232-41.  Back to cited text no. 16
[PUBMED]  [FULLTEXT]  
17.Reibaldi M, Cardascia N, Longo A, Furino C, Avitabile T, Faro S, et al. Standard-fluence versus low-fluence photodynamic therapy in chronic central serous chorioretinopathy: Nonrandomized clinical trial. Am J Ophthalmol 2010;149:307-15.  Back to cited text no. 17
[PUBMED]  [FULLTEXT]  
18.Marcuson J, Riley T. Central serous chorioretinopathy. Optometry 2008;79:241-51.  Back to cited text no. 18
[PUBMED]  [FULLTEXT]  
19.Otsuka S, Ohba N, Nakao K. A long-term follow-up study of severe variant of central serous chorioretinopathy. Retina 2002;22:25-32.  Back to cited text no. 19
[PUBMED]  [FULLTEXT]  
20.Wali UK, Al-Kharoosi N, Hamood H. Photodynamic therapy with verteporfin for central serous chorioretinopathy and idiopathic choroidal neovascularization: First report from Oman. Oman Med J 2008;23:282-6.  Back to cited text no. 20
    
21.Shin JY, Woo SJ, Yu HG, Park KH. Comparison of efficacy and safety between half-fluence and full-fluence photodynamic therapy for chronic central serous chorioretinopathy. Retina 2011;31:119-26.  Back to cited text no. 21
[PUBMED]    
22.Lim SJ, Roh MI, Kwon OW. Intravitreal bevacizumab injection for central serous chorioretinopathy. Retina 2010;30:100-6.  Back to cited text no. 22
[PUBMED]    
23.Pikkel J, Beiran I, Ophir A, Miller B. Acetazolamide for central serous retinopathy. Ophthalmology 2002;109:1723-5.  Back to cited text no. 23
[PUBMED]  [FULLTEXT]  


    Figures

  [Figure 1], [Figure 2], [Figure 3]
 
 
    Tables

  [Table 1], [Table 2]



 

Top
   
 
  Search
 
  
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
    Abstract
   Introduction
    Materials and Me...
   Results
   Discussion
    References
    Article Figures
    Article Tables

 Article Access Statistics
    Viewed3958    
    Printed159    
    Emailed0    
    PDF Downloaded407    
    Comments [Add]    

Recommend this journal